Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 6/2005

Open Access 01-12-2005 | Research article

CYP17 gene polymorphism in relation to breast cancer risk: a case-control study

Authors: Kristjana Einarsdóttir, Tove Rylander-Rudqvist, Keith Humphreys, Susanne Ahlberg, Gudrun Jonasdottir, Elisabete Weiderpass, Kee Seng Chia, Magnus Ingelman-Sundberg, Ingemar Persson, Jianjun Liu, Per Hall, Sara Wedrén

Published in: Breast Cancer Research | Issue 6/2005

Login to get access

Abstract

Introduction

The c.1-34T>C 5' promoter region polymorphism in cytochrome P450c17 (CYP17), a key enzyme in the biosynthesis of estrogen, has been associated with breast cancer risk, but most previous studies have been relatively small.

Methods

We genotyped 1,544 incident cases of primary breast cancer and 1,502 population controls, all postmenopausal Swedish women, for the CYP17 c.1-34T>C polymorphism and calculated odds ratios (ORs) and 95% confidence intervals (CIs) from logistic regression models.

Results

No overall association was found between CYP17 c.1-34T>C and breast cancer risk, OR 1.0 (95% CI 0.8–1.3) for the A2/A2 (CC) carriers compared to the A1/A1 (TT) carriers, regardless of histopathology. We detected an interaction between CYP17 c.1-34T>C and age at menarche (P = 0.026) but regarded that as a chance finding as no dose-response pattern was evident. Other breast cancer risk factors, including menopausal hormone use and diabetes mellitus, did not modify the overall results.

Conclusion

It is unlikely that CYP17 c.1-34T>C has a role in breast cancer etiology, overall or in combination with established non-genetic breast cancer risk factors.
Appendix
Available only for authorised users
Literature
1.
Bernstein L: Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia. 2002, 7: 3-15. 10.1023/A:1015714305420.CrossRefPubMed
2.
Nakajin S, Shinoda M, Haniu M, Shively JE, Hall PF: C21 steroid side chain cleavage enzyme from porcine adrenal microsomes. Purification and characterization of the 17 alpha-hydroxylase/C17,20-lyase cytochrome P-450. J Biol Chem. 1984, 259: 3971-3976.PubMed
3.
Picado-Leonard J, Miller WL: Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): similarity with the gene for P450c21. DNA. 1987, 6: 439-448.CrossRefPubMed
4.
Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R: Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet. 1994, 3: 1873-1876.CrossRefPubMed
5.
Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, Gabrielsen OS, Borresen-Dale AL: CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. Cancer Res. 1999, 59: 2825-2828.PubMed
6.
Chacko P, Rajan B, Mathew BS, Joseph T, Pillai MR: CYP17 and SULT1A1 gene polymorphisms in Indian breast cancer. Breast Cancer. 2004, 11: 380-388.CrossRefPubMed
7.
Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S: Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur J Cancer. 2000, 36: 2375-2379. 10.1016/S0959-8049(00)00334-8.CrossRefPubMed
8.
Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE: A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 1997, 57: 1063-1065.PubMed
9.
Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ: The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res. 1999, 59: 1015-1020.PubMed
10.
Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Vainio H, Uusitupa M, Hirvonen A: Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomarkers Prev. 2000, 9: 1343-1348.PubMed
11.
Ambrosone CB, Moysich KB, Furberg H, Freudenheim JL, Bowman ED, Ahmed S, Graham S, Vena JE, Shields PG: CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res. 2003, 5: R45-51. 10.1186/bcr570.CrossRefPubMedPubMedCentral
12.
Helzlsouer KJ, Huang HY, Strickland PT, Hoffman S, Alberg AJ, Comstock GW, Bell DA: Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol Biomarkers Prev. 1998, 7: 945-949.PubMed
13.
Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY: Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res. 1999, 59: 4870-4875.PubMed
14.
Gudmundsdottir K, Thorlacius S, Jonasson JG, Sigfusson BF, Tryggvadottir L, Eyfjord JE: CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status. Br J Cancer. 2003, 88: 933-936. 10.1038/sj.bjc.6600839.CrossRefPubMedPubMedCentral
15.
Weston A, Pan CF, Bleiweiss IJ, Ksieski HB, Roy N, Maloney N, Wolff MS: CYP17 genotype and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998, 7: 941-944.PubMed
16.
Hefler LA, Tempfer CB, Grimm C, Lebrecht A, Ulbrich E, Heinze G, Leodolter S, Schneeberger C, Mueller MW, Muendlein A, et al: Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer. 2004, 101: 264-269. 10.1002/cncr.20361.CrossRefPubMed
17.
Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PD, et al: Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst. 2004, 96: 936-945.CrossRefPubMed
18.
Wu AH, Seow A, Arakawa K, Van Den Berg D, Lee HP, Yu MC: HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer. 2003, 104: 450-457. 10.1002/ijc.10957.CrossRefPubMed
19.
Ahsan H, Whittemore AS, Chen Y, Senie RT, Hamilton SP, Wang Q, Gurvich I, Santella RM: Variants in estrogen-biosynthesis genes CYP17 and CYP19 and breast cancer risk: a family-based genetic association study. Breast Cancer Res. 2005, 7: R71-81. 10.1186/bcr951.CrossRefPubMed
20.
Verla-Tebit E, Wang-Gohrke S, Chang-Claude J: CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study. Breast Cancer Res. 2005, 7: R455-464. 10.1186/bcr1027.CrossRefPubMedPubMedCentral
21.
Chang JH, Gertig DM, Chen X, Dite GS, Jenkins MA, Milne RL, Southey MC, McCredie MR, Giles GG, Chenevix-Trench G, et al: CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study. Breast Cancer Res. 2005, 7: R513-521. 10.1186/bcr1040.CrossRefPubMedPubMedCentral
22.
Ye Z, Parry JM: The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis. 2002, 17: 119-126. 10.1093/mutage/17.2.119.CrossRefPubMed
23.
Feigelson HS, McKean-Cowdin R, Henderson BE: Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis. 2002, 17: 445-446. 10.1093/mutage/17.5.445. author reply 447–448CrossRefPubMed
24.
Magnusson C, Colditz G, Rosner B, Bergstrom R, Persson I: Association of family history and other risk factors with breast cancer risk (Sweden). Cancer Causes Control. 1998, 9: 259-267. 10.1023/A:1008817018942.CrossRefPubMed
25.
Magnusson CM, Persson IR, Baron JA, Ekbom A, Bergstrom R, Adami HO: The role of reproductive factors and use of oral contraceptives in the aetiology of breast cancer in women aged 50 to 74 years. Int J Cancer. 1999, 80: 231-236. 10.1002/(SICI)1097-0215(19990118)80:2<231::AID-IJC11>3.0.CO;2-R.CrossRefPubMed
26.
Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I: Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer. 1999, 81: 339-344. 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6.CrossRefPubMed
27.
Moradi T, Nyren O, Zack M, Magnusson C, Persson I, Adami HO: Breast cancer risk and lifetime leisure-time and occupational physical activity (Sweden). Cancer Causes Control. 2000, 11: 523-531. 10.1023/A:1008900512471.CrossRefPubMed
28.
Terry P, Wolk A, Persson I, Magnusson C: Brassica vegetables and breast cancer risk. JAMA. 2001, 285: 2975-2977. 10.1001/jama.285.23.2975.CrossRefPubMed
29.
Isola J, DeVries S, Chu L, Ghazvini S, Waldman F: Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Pathol. 1994, 145: 1301-1308.PubMedPubMedCentral
30.
Pastinen T, Partanen J, Syvanen AC: Multiplex, fluorescent, solid-phase minisequencing for efficient screening of DNA sequence variation. Clin Chem. 1996, 42: 1391-1397.PubMed
31.
Prince JA, Feuk L, Howell WM, Jobs M, Emahazion T, Blennow K, Brookes AJ: Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation. Genome Res. 2001, 11: 152-162. 10.1101/gr.150201.CrossRefPubMedPubMedCentral
32.
Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE: Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res. 1998, 58: 585-587.PubMed
33.
Magnusson C, Baron J, Persson I, Wolk A, Bergstrom R, Trichopoulos D, Adami HO: Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer. 1998, 76: 29-34. 10.1002/(SICI)1097-0215(19980330)76:1<29::AID-IJC6>3.0.CO;2-#.CrossRefPubMed
34.
Kaaks R: Nutrition, hormones, and breast cancer: is insulin the missing link?. Cancer Causes Control. 1996, 7: 605-625. 10.1007/BF00051703.CrossRefPubMed
35.
Wedren S, Rudqvist TR, Granath F, Weiderpass E, Ingelman-Sundberg M, Persson I, Magnusson C: Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk. Carcinogenesis. 2003, 24: 681-687. 10.1093/carcin/bgg022.CrossRefPubMed
36.
Rylander-Rudqvist T, Wedren S, Granath F, Humphreys K, Ahlberg S, Weiderpass E, Oscarson M, Ingelman-Sundberg M, Persson I: Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis. 2003, 24: 1533-1539. 10.1093/carcin/bgg114.CrossRefPubMed
37.
Wedren S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvanen AC, Kindmark A, Landegren U, Fermer ML, Stiger F, et al: Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res. 2004, 6: R437-449. 10.1186/bcr811.CrossRefPubMedPubMedCentral
38.
Daneshmand S, Weitsman SR, Navab A, Jakimiuk AJ, Magoffin DA: Overexpression of theca-cell messenger RNA in polycystic ovary syndrome does not correlate with polymorphisms in the cholesterol side-chain cleavage and 17alpha-hydroxylase/C(17–20) lyase promoters. Fertil Steril. 2002, 77: 274-280. 10.1016/S0015-0282(01)02999-5.CrossRefPubMed
39.
Sharp L, Cardy AH, Cotton SC, Little J: CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors. a HuGE review. Am J Epidemiol. 2004, 160: 729-740. 10.1093/aje/kwh287.CrossRefPubMed
40.
Hong CC, Thompson HJ, Jiang C, Hammond GL, Tritchler D, Yaffe M, Boyd NF: Association between the T27C polymorphism in the cytochrome P450 c17alpha (CYP17) gene and risk factors for breast cancer. Breast Cancer Res Treat. 2004, 88: 217-230. 10.1007/s10549-004-0780-7.CrossRefPubMed
41.
Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, et al: Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2004, 13: 94-101.CrossRefPubMed
42.
Garcia-Closas M, Herbstman J, Schiffman M, Glass A, Dorgan JF: Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre-menopausal women. Int J Cancer. 2002, 102: 172-178. 10.1002/ijc.10651.CrossRefPubMed
43.
Hamajima N, Iwata H, Obata Y, Matsuo K, Mizutani M, Iwase T, Miura S, Okuma K, Ohashi K, Tajima K: No association of the 5' promoter region polymorphism of CYP17 with breast cancer risk in Japan. Jpn J Cancer Res. 2000, 91: 880-885.CrossRefPubMed
44.
Gorai I, Tanaka K, Inada M, Morinaga H, Uchiyama Y, Kikuchi R, Chaki O, Hirahara F: Estrogen-metabolizing gene polymorphisms, but not estrogen receptor-alpha gene polymorphisms, are associated with the onset of menarche in healthy postmenopausal Japanese women. J Clin Endocrinol Metab. 2003, 88: 799-803. 10.1210/jc.2002-020353.CrossRefPubMed
45.
Lai J, Vesprini D, Chu W, Jernstrom H, Narod SA: CYP gene polymorphisms and early menarche. Mol Genet Metab. 2001, 74: 449-457. 10.1006/mgme.2001.3260.CrossRefPubMed
46.
Dunning AM, Healey CS, Pharoah PD, Foster NA, Lipscombe JM, Redman KL, Easton DF, Day NE, Ponder BA: No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer. 1998, 77: 2045-2047.CrossRefPubMedPubMedCentral
47.
Goodman MT, McDuffie K, Guo C, Terada K, Donlon TA: CYP17 genotype and ovarian cancer: a null case-control study. Cancer Epidemiol Biomarkers Prev. 2001, 10: 563-564.PubMed
48.
Feigelson HS, McKean-Cowdin R, Pike MC, Coetzee GA, Kolonel LN, Nomura AM, Le Marchand L, Henderson BE: Cytochrome P450c17alpha gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res. 1999, 59: 3908-3910.PubMed
49.
Haiman CA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I: A polymorphism in CYP17 and endometrial cancer risk. Cancer Res. 2001, 61: 3955-3960.PubMed
50.
McKean-Cowdin R, Feigelson HS, Pike MC, Coetzee GA, Kolonel LN, Henderson BE: Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res. 2001, 61: 848-849.PubMed
Metadata
Title
CYP17 gene polymorphism in relation to breast cancer risk: a case-control study
Authors
Kristjana Einarsdóttir
Tove Rylander-Rudqvist
Keith Humphreys
Susanne Ahlberg
Gudrun Jonasdottir
Elisabete Weiderpass
Kee Seng Chia
Magnus Ingelman-Sundberg
Ingemar Persson
Jianjun Liu
Per Hall
Sara Wedrén
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1319

Other articles of this Issue 6/2005

Breast Cancer Research 6/2005 Go to the issue

Research article

Dehydroepiandrosterone inhibits the progression phase of mammary carcinogenesis by inducing cellular senescence via a p16-dependent but p53-independent mechanism

Research article

Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis

Research article

Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model system

Commentary

Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions

Research article

Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ

Review

Overdiagnosis and overtreatment of breast cancer: Overdiagnosis and overtreatment in service screening
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits